Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Raltegravir 400 mg
DRUG
2 trials
Sponsors
ViiV Healthcare
, Helen Reynolds
Conditions
HIV
Infection, Human Immunodeficiency Virus
Phase 1
The Effect of Antacids and Multivitamins on Raltegravir
Completed
NCT01784302
Helen Reynolds
HIV
Start: 2014-04-30
End: 2016-02-29
Updated: 2016-02-25
Phase 2
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Completed
NCT01384734
ViiV Healthcare
Infection, Human Immunodeficiency Virus
Start: 2011-07-26
End: 2017-05-12
Updated: 2018-11-14
Related Papers
Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
2022-03-22
8 citations
Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Antiretroviral-Experienced Subjects: Week 48 Analysis of AI438011, a Phase IIb, Randomized Controlled Trial
Antiviral Therapy
2016-04-01
30 citations
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529
Antimicrobial Agents and Chemotherapy
2016-02-23
21 citations
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
2015-09-01
49 citations